298 related articles for article (PubMed ID: 32579503)
1. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment.
Singh A; Shafi S; Upadhyay T; Najmi AK; Kohli K; Pottoo FH
Curr Top Med Chem; 2020; 20(20):1839-1854. PubMed ID: 32579503
[TBL] [Abstract][Full Text] [Related]
2. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
[TBL] [Abstract][Full Text] [Related]
3. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.
Kumar V; Rahman M; Gahtori P; Al-Abbasi F; Anwar F; Kim HS
Expert Opin Drug Deliv; 2021 Jun; 18(6):673-694. PubMed ID: 33295218
[TBL] [Abstract][Full Text] [Related]
4. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
5. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma.
Elnaggar MH; Abushouk AI; Hassan AHE; Lamloum HM; Benmelouka A; Moatamed SA; Abd-Elmegeed H; Attia S; Samir A; Amr N; Johar D; Zaky S
Semin Cancer Biol; 2021 Feb; 69():91-99. PubMed ID: 31421265
[TBL] [Abstract][Full Text] [Related]
7. The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma.
Zhang Z; Song L; Guo J
Pharm Nanotechnol; 2018; 6(4):221-231. PubMed ID: 30277174
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in hepatocellular carcinoma-targeted nanoparticles.
Liu X; Bai Y; Zhou B; Yao W; Song S; Liu J; Zheng C
Biomed Mater; 2024 May; 19(4):. PubMed ID: 38697209
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
10. Advanced therapeutics avenues in hepatocellular carcinoma: a novel paradigm.
Javed ; Yadav S
Med Oncol; 2023 Jul; 40(8):239. PubMed ID: 37442842
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicines: a theranostic approach for hepatocellular carcinoma.
Usmani A; Mishra A; Ahmad M
Artif Cells Nanomed Biotechnol; 2018 Jun; 46(4):680-690. PubMed ID: 28884605
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Nanoparticles for Hepatocellular Carcinoma Diagnosis and Therapy.
Ungureanu BS; Teodorescu CM; Săftoiu A
J Gastrointestin Liver Dis; 2016 Sep; 25(3):375-83. PubMed ID: 27689203
[TBL] [Abstract][Full Text] [Related]
13. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
[TBL] [Abstract][Full Text] [Related]
14. Conventional and hybrid nanoparticulate systems for the treatment of hepatocellular carcinoma: An updated review.
Fawzi Kabil M; Nasr M; El-Sherbiny IM
Eur J Pharm Biopharm; 2021 Oct; 167():9-37. PubMed ID: 34271117
[TBL] [Abstract][Full Text] [Related]
15. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
[TBL] [Abstract][Full Text] [Related]
16. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.
Li M; Zhang W; Wang B; Gao Y; Song Z; Zheng QC
Int J Nanomedicine; 2016; 11():5645-5669. PubMed ID: 27920520
[TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
[No Abstract] [Full Text] [Related]
18. Nanophytomedicine Based Novel Therapeutic Strategies in Liver Cancer.
Kumar S; Fayaz F; Pottoo FH; Bajaj S; Manchanda S; Bansal H
Curr Top Med Chem; 2020; 20(22):1999-2024. PubMed ID: 31724500
[TBL] [Abstract][Full Text] [Related]
19. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
20. Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma.
Hou XY; Jiang G; Yang CS; Tang JQ; Wei ZP; Liu YQ
Recent Pat Anticancer Drug Discov; 2016; 11(3):322-31. PubMed ID: 26955964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
